Association Between Aspirin and Cholangiocarcinoma in a Large Asian Cohort

Menée à partir de données de l'Assurance maladie coréenne portant sur 922 patients atteints d'un cholangiocarcinome et sur 4 610 témoins (âge : au moins 40 ans ; 61 % d'hommes), cette étude analyse l'association entre une utilisation d'aspirine sur une durée de 4 ans (2002-2006) et le risque de développer la maladie

Résumé en anglais

A few observational studies have investigated aspirin as a potential chemopreventive agent for cholangiocarcinomas (CCAs), but the evidence is still limited. Petrick et al analyzed US-based cohorts, but medication information was based on self-report. Choi et al and Altaii et al analyzed US hospital-based case-control data, but duration and dose information was limited. A meta-analysis reported a pooled odds ratio of 0.56 (95% CI, 0.32-0.96), but the interpretability is limited because of the significant heterogeneity (I2, 98%). As prevention trials may not be feasible because of the low incidence of CCA, we sought to address the question using a well-designed observational study.